Yellow Fever Vaccine Market Report 2024

The yellow fever vaccine market size has grown strongly in recent years. It will grow from $4.32 billion in 2023 to $4.54 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to several factors, including the initiation of global immunization campaigns aimed at preventing infectious diseases such as yellow fever, implementation of international health regulations to control disease spread, widespread mass vaccination campaigns targeting vulnerable populations, and advancements in vaccine production technology enhancing vaccine availability and efficacy.

The yellow fever vaccine market size is expected to see strong growth in the next few years. It will grow to $5.56 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increased collaboration and partnerships among global health entities, integration of yellow fever vaccination with routine immunization schedules, enhanced surveillance and monitoring of vaccine effectiveness and safety, greater involvement of the private sector in vaccine distribution and administration, and adoption of digital technologies for efficient vaccine tracking and management. Major trends expected in this period include diversification of vaccine formats to meet varying population needs, enhanced pandemic preparedness strategies focusing on rapid vaccine deployment, regulatory changes to streamline vaccine approval and distribution processes, improvements in healthcare infrastructure to support vaccination efforts, and increased consumer education and awareness campaigns to promote vaccination benefits and safety.

The yellow fever vaccine market is poised for growth driven by increasing international travel. International travel involves the movement of individuals across borders for tourism, business, or personal reasons and is on the rise due to enhanced global connectivity, economic expansion, and eased travel restrictions post-pandemic. The yellow fever vaccine is crucial for travelers visiting regions where yellow fever is endemic to prevent infection and comply with international health guidelines. For example, the World Tourism Organization reported in January 2024 that global international tourists (overnight visitors) reached 1.286 billion in 2023, marking a significant increase from 960 million in 2022. This surge highlights the growing demand for the yellow fever vaccine.

Leading companies in the yellow fever vaccine market are concentrating on developing advanced next-generation vaccines, such as the T-cell adaptive booster vaccine, to meet the rising global demand for vaccines. The T-cell adaptive booster vaccine is designed to enhance the immune system's memory T-cell response, ensuring prolonged and robust immunity against specific pathogens. For instance, Emergex Vaccines Holding Limited, a UK-based biotechnology company, partnered with ATCC, a US-based non-profit organization, in April 2022 to introduce CD8+ T-cell adaptive vaccines tailored for yellow fever. These vaccines stimulate a potent cytotoxic T-cell response critical for identifying and eliminating virus-infected cells. By promoting memory CD8+ T-cell production, these vaccines provide durable protection against yellow fever by focusing on cellular immunity, complementing traditional antibody-based approaches.

In October 2022, Emergex Vaccines Holding Limited expanded its capabilities by acquiring the assets of Zosano Pharma Corporation, a US-based pharmaceutical company specializing in transdermal delivery systems. This acquisition strengthens Emergex Vaccines' vaccine delivery methods, enhancing its ability to develop and commercialize innovative vaccines, including those targeting yellow fever.

Major companies operating in the yellow fever vaccine market are Merck and Co Inc., Sanofi S.A., GSK plc, Takeda Pharmaceutical Company, Lonza Group Ag, WuXi Biologics, Novavax Inc., Beijing Tiantan Biological, Bavarian Nordic A/S, Valneva SE, Biological E. Limited, Bio-Manguinhos, Instituto Butantan, Bio Farma, Panacea Biotec, Biovac, Institut Pasteur de Dakar, Ology Bioservices, Gavi, Wuhan Institute of Biological Products, PnuVax Incorporated, iBio Inc.

North America was the largest region in the yellow fever vaccine market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yellow fever vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the yellow fever vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The yellow fever vaccine is a live, attenuated viral vaccine used to prevent yellow fever, a serious viral infection transmitted by mosquitoes. It is typically administered as a single dose and provides long-lasting immunity, often lifelong. The vaccine is crucial for individuals residing in or traveling to areas where yellow fever is endemic.

The main presentations of the yellow fever vaccine include powder and liquid forms. Yellow fever vaccine powder is lyophilized (freeze-dried), requiring reconstitution with a specific diluent before administration to confer immunity against the yellow fever virus. This vaccine is utilized for routine immunization, travelers' vaccinations, and other applications, and is distributed through various channels including hospitals, diagnostic centers, and point-of-care facilities.

The yellow fever vaccine market research report is one of a series of new reports that provides yellow fever vaccine market statistics, including yellow fever vaccine industry global market size, regional shares, competitors with a yellow fever vaccine market share, detailed yellow fever vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the yellow fever vaccine industry. This yellow fever vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yellow fever vaccine market consists of sales of vaccine syringes, needles, and vaccine storage equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.